Filing Flows › Neogenomics (NEO) › How it makes money
How Neogenomics (NEO) makes money
Neogenomics (NEO) made $209M of revenue in the third quarter 2026 (Q3 2026), +11% from a year earlier. Client direct billing brought in $136M (65%); Commercial insurance brought in $44.7M (21%); Medicare and other government brought in $29.0M (14%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Client direct billing | $136M | 64.8% | -2% | +2% |
| Commercial insurance | $44.7M | 21.3% | +23% | +38% |
| Medicare and other government | $29.0M | 13.9% | +6% | +26% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $209M | 100.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $209M | +11% |
| Q2 2026 | $202M | +11% |
| Q1 2026 | $187M | +11% |
| Q4 2025 | $190M | +11% |
| Q3 2025 | $188M | +12% |
| Q2 2025 | $181M | +10% |
| Q1 2025 | $168M | +8% |
From Neogenomics' 10-Q filed Oct 28, 2026 (on EDGAR).
Questions
How does Neogenomics make money?
Neogenomics (NEO) made $209M of revenue in the third quarter 2026 (Q3 2026), +11% from a year earlier. Client direct billing brought in $136M (65%); Commercial insurance brought in $44.7M (21%); Medicare and other government brought in $29.0M (14%).
What is Neogenomics' biggest business?
Client direct billing: $136M in the third quarter 2026, 65% of revenue, +2% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.